351
Participants
Start Date
September 15, 2017
Primary Completion Date
May 7, 2018
Study Completion Date
April 24, 2019
KX2-391 Ointment 1%
Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
Placebo
Dosage form: Ointment; Route of administration: Topical
Union Square Laser Dermatology, New York
The Education & Research Foundation, Inc., Lynchburg
Clinical Research Center of the Carolinas, Charleston
Sweet Hope Research Specialty, Inc., Miami Lakes
Study Protocol, Inc, Boynton Beach
Forward Clinical Trials, Inc., Tampa
Rivergate Dermatology Clinical Research, Springfield
Dermatology Associates Of Knoxville, PC, Knoxville
DS Research, Louisville
Aventiv Research Inc., Dublin
Laser & Skin Surgery Center of Indiana, Carmel
Dawes Fretzin Clinical Research Group, Indianapolis
Hamzavi Dermatology, Fort Gratiot
Medisearch Clinical Trials, Saint Joseph
Clinical Trials of SWLA, LLC, Lake Charles
Burke Pharmaceutical Research, Hot Springs
Suzanne Bruce and Associates, P.A., The Center for Skin Research, Houston
Clinical Trials of Texas, Inc., San Antonio
DermResearch, Austin
AboutSkin Dermatology, Greenwood Village
Alliance Dermatology, Phoenix
Synexus US, Tucson
Henderson Dermatology Research, Henderson
Dermatology Specialists, Inc., Oceanside
Skin Surgery Medical Group, Inc., San Diego
Dermatology Specialists, Inc., Murrieta
Synexus, Santa Rosa
Oregon Medical Research Center, Portland
Dermatology Associates of Seattle, Seattle
Activmed Practices & Research, Inc, Portsmouth
Lead Sponsor
Collaborators (1)
Athenex, Inc.
INDUSTRY
Almirall, S.A.
INDUSTRY